Fresenius SE & CO KGaA : 2019 margin under pressure; 2020 target will not be met; cut to Neutral
>2019 outlook: Tough comparison base for Kabi; Helios EBIT to contract - Fresenius SE (FRE) expects to achieve mid-single-digit organic sales growth in 2019 (Oddo BHFe: 6%; cons: 5%) and broadly stable group net income (Oddo BHFe: +3.8%; cons.: +6%). For 2019, Fresenius Medical Care currently broadly assumes solid comparable sales growth and comparable net income close to the 2018 level. Kabi had a very strong 2018, which makes for a tough comparison base for 20...Fresenius is a health care group providing products and services for dialysis, hospitals and outpatient medical care. Co. operates four business segments: Fresenius Medical Care; Fresenius Kabi; Fresenius Helios; and Fresenius Vamed. Fresenius Medical Care provides dialysis care and dialysis products for patients with chronic kidney failure. Fresenius Kabi is engaged in the provision of generic drugs, infusion therapies, clinical nutrition products, related medical devices and transfusion technology. Fresenius Vamed manages projects and provides services for hospitals and other health care facilities. Fresenius Helios is a private hospital operator which only operates in Germany.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.